NCT06971874 The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome
| NCT ID | NCT06971874 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Condition | Chronic Kidney Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 356 participants |
| Start Date | 2025-07-17 |
| Primary Completion | 2029-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 356 participants in total. It began in 2025-07-17 with a primary completion date of 2029-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Obstructive sleep apnea (OSA) is highly prevalent in chronic kidney disease (CKD) patients and strongly linked to obesity, metabolic syndrome, and type 2 diabetes. Besides elevating cardiovascular disease risk, OSA may worsen renal function and diminish quality of life, making its understanding critical for CKD patient health. This study will establish a large, long-term cohort of non-dialysis CKD patients to identify OSA risk factors, explore OSA's association with adverse renal outcomes, and determine OSA prevalence and epidemiological characteristics within the CKD population. The findings will provide a scientific foundation for early OSA identification, diagnosis, and intervention in CKD patients.
Eligibility Criteria
Inclusion Criteria: * Voluntarily sign the informed consent form; * Aged ≥ 18 years and \< 75 years; * Patients with CKD stages 3-4, with an eGFR of 15-60 ml/min/1.73m² calculated using the CKD-EPI formula for at least 3 months. Exclusion Criteria: * Patients receiving oxygen therapy or continuous positive airway pressure (CPAP) treatment; * Patients with other sleep disorders, including restless legs syndrome, periodic limb movement disorder, etc.; * Patients with other severe comorbidities: Severe heart failure (NYHA class III or IV); Myocardial infarction, unstable angina, or stroke within the past 3 months; Severe arrhythmias requiring medication or device therapy; Respiratory diseases, including COPD, asthma, thoracic deformities, etc.; Neurological disorders, including myasthenia gravis, Parkinson's disease, Alzheimer's disease, etc.; Active liver disease or severe hepatic insufficiency; Psychiatric conditions, including depression, anxiety disorders, etc.; History of malignancy within the past 5 years (except cured basal cell carcinoma); Uncontrolled hyperthyroidism; * Patients who underwent surgery or had acute infections within the past 3 months; * Current heavy alcohol consumption:Females: \>3 drinks/day or \>7 drinks/week; Males: \>4 drinks/day or \>14 drinks/week (1 standard drink = 14g of alcohol) * Current use of medications that may severely interfere with sleep, such as antipsychotics, antiepileptics, antiparkinsonian drugs, antidepressants, opioids, etc.; * Females who are pregnant or lactating at screening or baseline; * Inability to comply with the study due to: Low education level, language barriers, inability to tolerate or complete sleep monitoring, or other reasons preventing completion of study procedures (e.g., follow-up); * Deemed unsuitable for participation by the investigator's judgment.
Frequently Asked Questions
Who can join the NCT06971874 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06971874 currently recruiting?
Yes, NCT06971874 is actively recruiting participants. Visit ClinicalTrials.gov or contact Nanfang Hospital, Southern Medical University to inquire about joining.
Where is the NCT06971874 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06971874 clinical trial?
NCT06971874 is sponsored by Nanfang Hospital, Southern Medical University. The trial plans to enroll 356 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.